Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics and Pacira BioSciences Are Moving in Opposite Directions Today

By George Budwell - Updated May 1, 2019 at 1:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heron's pain is Pacira's gain.

What happened

Heron Therapeutics (HRTX 2.59%) and Pacira BioSciences (PCRX 2.65%) are moving in polar opposite directions today. As of 11:40 a.m EDT, Heron's stock was down by 14.7%, whereas Pacira's shares were up by 15.5%.  

These two mid-cap biotech stocks are both responding to the news that the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Heron's experimental post-operative pain medication HTX-011. The agency reportedly cited the need for additional Chemistry, Manufacturing and Controls data, as well as other nonclinical information, as the reason for the CRL. On the plus side, Heron's management noted in a conference call this morning that the FDA didn't base its decision on any outstanding clinical or safety issue, meaning that more time-consuming clinical studies probably won't be required to get the drug approved.

A man in a suit staring at a black wall with one large yellow arrow pointing in one direction, and several smaller white arrows pointed in the opposite direction.

Image source: Getty Images.

So what

Heron's extended release pain medication is slated to compete directly against Pacira's Exparel in several key market segments. The two drugs share a common component (bupivacaine), but Heron's formulation of the pain reliever seems to be superior at reducing the need for opioid use in the post-operative setting. Thus, HTX-011 should have a decent shot at cutting deeply into Exparel's share of the market following approval. So, with this major competitive threat delayed for a little while longer, it's easy to see why Pacira's shareholders are cheering this news today. 

Now what

If the FDA isn't going to require another trial, Heron should be able to get this regulatory filing back to the agency within a matter of months. So while this CRL is certainly unwelcome news, it shouldn't turn out to be a showstopper. Bargain hunters, in turn, might want to take advantage of this hefty drop by picking up some shares of this beaten-down biotech stock soon.

On the flip side, investors may want to take a cautious approach toward Pacira's stock following this double-digit rally. Although the regulatory delay does provide some much-needed breathing room for Pacira, it in no way eliminates the competitive threat emanating from HTX-011. Pacira's stock, therefore, may have trouble holding on to these sizable gains.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$3.57 (2.59%) $0.09
Pacira BioSciences, Inc. Stock Quote
Pacira BioSciences, Inc.
PCRX
$63.04 (2.65%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.